Adaptive tDCS for Treatment-Resistant MDD
NCT: NCT02942368 · TERMINATED
Brief Summary
This pilot study aims to investigate the potential role of transcranial direct current stimulation (tDCS) in the treatment of treatment-resistant major depressive disorder (MDD). tDCS is a noninvasive brain stimulation technique which has been utilized for the treatment of major depression in several studies, both as a primary and adjunctive treatment. The treatment will be administered under the supervision of a physician with experience in administering the treatment and monitoring for complications. This will be a prospective "adaptive tDCS stimulation" open label research study. Participants will receive 20 minute sessions of up to 4 milliamps (mA) transcutaneous electrical stimulation sessions over 4 to 6 weeks. Building on the theory that greater current "dose" may be a significant factor in determining efficacy, this study aims to determine whether higher tDCS current doses lead to greater improvements in depressive symptoms in this population of patients with treatment-resistant major depressive disorder.
Frequently Asked Questions
What is Adaptive tDCS for Treatment-Resistant MDD?
Adaptive tDCS for Treatment-Resistant MDD is a clinical trial registered under NCT02942368. Current status: TERMINATED.
What is the status of NCT02942368?
The current status of NCT02942368 (Adaptive tDCS for Treatment-Resistant MDD) is: TERMINATED.
When did Adaptive tDCS for Treatment-Resistant MDD start?
Adaptive tDCS for Treatment-Resistant MDD started on 2017-04-14.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.